(31 March, 2026, Shanghai China) On 31 March 2026, Fosun Pharma (600196.SH; 02196.HK) announced that it has received the approval from the National Medical Products Administration (NMPA) to initiate a clinical trial of FXB0871 for the treatment of locally advanced or metastatic solid tumors. Fosun Pharmaceutical Industrial Development Co., Ltd., a subsidiary of Fosun Pharma plans to initiate the Phase 1 clinical study of FXB0871 in Chinese Mainland upon fulfillment of relevant conditions.

FXB0871 (referred to as TEV-56278 outside of Fosun Pharma territory) is an anti-PD1-IL2 ATTENUKINE™ therapy being co-developed by Fosun Pharma and Teva Pharmaceutical Industries Ltd. (Teva, NYSE & TASE: TEVA). The Teva-developed ATTENUKINE technology provides a new mechanism of action, potentially offering high efficacy and low toxicity in a broad array of oncology indications. It is being evaluated as a monotherapy across a variety of tumor types. Pre-clinical data has demonstrated tumor regression, enhanced T-cell infiltration, and durable immune memory.

As per the terms of the agreement, Fosun Pharma holds the exclusive rights for the development, manufacturing and commercialization of this product in China (including Hong Kong SAR, Macau SAR and Taiwan region) and agreed Southeast Asian countries. Teva retains all development, manufacturing and commercialization rights to the licensed molecule in the rest of the world. The two parties will share clinical data to jointly accelerate the research and development progress of this innovative therapy.

A global multi-center phase 1 study of TEV-56278 / FXB0871 is underway in the United States and Canada. The approval of FXB0871's Phase 1 clinical trial expands the global clinical development of this promising compound in China. Leveraging its advantages in localized R&D and clinical practice, Fosun Pharma will expedite the launch of this cutting-edge innovative therapy in China, with the goal of bringing innovative treatments to patients faster.

As an innovation-driven global pharmaceutical and healthcare group,Fosun Pharma has established an open, global R&D system. In order to address unmet clinical needs, we focus on key therapeutic areas including oncology, immunology, inflammation and neurodegenerative diseases, while also expanding into chronic and rare diseases. This approach enables us to build a sustainable and competitive pipeline and deliver integrated solutions. Meanwhile, we are strengthening our core technology platforms in antibodies and ADCs, small molecules and cell therapy, while exploring frontier areas such as radiopharmaceuticals and small nucleic acids. By enhancing early-stage innovation capabilities, we are accelerating the clinical translation of scientific research.

***

"ATTENUKINE™ is a registered trademark of Teva Pharmaceutical Industries Ltd."

About Fosun Pharma

Founded in 1994, Fosun Pharma (stock code: 600196.SH; 02196.HK) is an innovation-driven global pharmaceutical and healthcare group. With the mission of Better Health for Families Worldwide, we focus on developing innovative medicines, medical technologies and diagnostics as well as delivering healthcare services. Through our business partner Sinopharm Group, we have also established pharmaceutical distribution network, built a comprehensive pharmaceutical and healthcare ecosystem.

Fosun Pharma is dedicated to innovation and globalization. The company has established a global R&D innovation system targeting at unmet medical needs. Our strategic focus is on key therapeutic areas including oncology, immunology and inflammation, neurodegenerative diseases, and selected cardiometabolic diseases and rare diseases. This approach enables the development of high valued competitive pipelines and comprehensive healthcare solutions. Meanwhile, Fosun Pharma has consolidated its core technical platforms including but not limited to antibodies and antibody-drug conjugates (ADC), small molecules and cell therapy. Additionally, we also actively advance cutting-edge therapeutic modalities such as radiopharmaceuticals and small nucleic acids. These efforts have strengthened our early-stage innovative portfolios and accelerated the transformation of scientific discoveries to drug development. Our innovative products are now available in more than 90 countries and regions worldwide, including major markets across China, the United States, Europe, Africa, India and Southeast Asia.

Looking ahead, guided by the strategy of “Innovation Driven, Deep Globalization, and AI Embracement”, Fosun Pharma remains committed to its core values: Care for life, Continuous innovation, Pursuit of excellence and Sustainable partnership. We strive to become a leading global healthcare innovation integrator, ensuring that the benefits of medical innovation reach more patients worldwide, and contribute to safeguarding human health.

For more information about the Group, please visit the company website: https://www.fosunpharma.com/en/